Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Oct 13, 2026
Biodexa Pharmaceuticals filed Prospectus Supplement No. 5 to its F-1 registration statement, incorporating a Form 6-K dated October 8, 2026 into the prospectus covering warrant shares from its December 2025 best-efforts offering. The 6-K announces a mandatory ADS ratio change from 1 ADS per 50 ordinary shares to 1 ADS per 400 ordinary shares, effective on or about October 26, 2026. Holders must surrender every eight old ADSs for one new ADS (new CUSIP 59564R864), with JPMorgan Chase Bank as depositary handling the exchange.
Key figures
- New ads ratio
- 1 ADS : 400 ordinary shares
- Old ads ratio
- 1 ADS : 50 ordinary shares
- Effective date
- 2026-10-26
- Last closing price
- 0.3832
- Reverse split ratio
- 1-for-8 (ADS level)
- Shares underlying series l warrants
- 60975600
- Shares underlying pre funded warrants
- 4890000
- Shares underlying placement agent warrants
- 1524350
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.